Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors

Immunotherapy by chimeric antigen receptor (CAR)-modified T-cells has shown unprecedented clinical efficacy for hematological malignancies. Recently two CAR T-cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) were approved by the US Food and Drug Administrati...

Descripción completa

Detalles Bibliográficos
Autores principales: Alcantara, Marion, Du Rusquec, Pauline, Romano, Emanuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466853/
https://www.ncbi.nlm.nih.gov/pubmed/32934880
http://dx.doi.org/10.1080/2162402X.2020.1777064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466853/
https://www.ncbi.nlm.nih.gov/pubmed/32934880
http://dx.doi.org/10.1080/2162402X.2020.1777064

Ejemplares similares